Biology subjects

Bhutada, S.

Publications and source records attributed to Bhutada, S..

3 recordsLinked to original sources

bioRxiv2026

Pan-cancer discovery of driver mutations in long noncoding RNAs reveals widespread functional rewiring of RNA regulatory elements

Most somatic mutations in cancer occur outside protein-coding genes, yet the functional impact of these mutations remains largely unknown. Long noncoding RNAs (lncRNAs) represent a major class of cancer-promoting genes whose molecular mechanisms are poorly understood. While individual driver mutations in lncRNAs have been identified, detecting such driver lncRNAs at scale requires large tumour genome cohorts. We analyse 12,631 cancer genomes from the 100,000 Genomes Project (100kGP) and identify 121 lncRNAs under positive selection across 19 cancer types. These driver lncRNAs are independently supported by functional genomic screens, germline predisposing variants, mutual exclusivity with protein-coding drivers, and independent oncogenic lncRNA catalogues. Overall, approximately two-thirds of analysed tumours harbour at least one lncRNA driver mutation. Leveraging the depth of this dataset, we demonstrate that somatic mutations preferentially target and remodel RNA-binding protein (RBP) interaction sites to potentiate oncogenic lncRNAs, including MALAT1, SNHG14 and NEAT1. From these data, we derive a model in which somatic mutations liberate oncogenic lncRNAs from repressive RNA:protein interactions. This work expands the number and nature of cancer driver genes, identifies targets for RNA-directed therapies, and demonstrates that with large tumour mutation catalogues we can dissect the molecular mechanisms of noncoding genes.

Cancer Biology↗

bioRxiv2024

Integrated forward and reverse degradomics uncovers the proteolytic landscape of aortic aneurysms and the roles of MMP9 and mast cell chymase

BackgroundDysregulated proteolysis is implicated in thoracic (TAA) and abdominal aortic aneurysm (AAA) pathogenesis, but the proteolytic landscapes (degradomes) of aneurysmal and normal aorta, and contributions of individual proteases remain undefined. Here, a proteome-wide approach was used to uncover TAA and AAA degradomes, compare them quantitatively and define the specific role in aortic remodeling of two proteases consistently identified in the aneurysms, mast cell chymase (CMA1) and matrix metalloprotease 9 (MMP9). MethodsThe mass spectrometry-based N-terminomics strategy Terminal Amine Isotopic Labeling of Substrates (TAILS) was applied to Marfan syndrome TAAs (n=5), AAAs (n=16) and corresponding non-diseased aorta (TAs, n=4, and AAs, n=8) as a forward degradomics application, i.e., to define substrate and protease degradomes, and 8-plex iTRAQ-TAILS was used for quantitative comparison. Cleavage sites of CMA1 and MMP9 were sought by reverse degradomics, i.e., digestion of aortic proteins with these proteases, followed by 6-plex iTRAQ-TAILS. CMA1 and MMP9 proteolysis of biglycan was investigated using Amino-Terminal Oriented Mass spectrometry of Substrates (ATOMS). ResultsWe experimentally annotated 16,923 proteolytically derived peptides (substrate degradome) and 90 proteases (protease degradome) in the aorta. Quantitative substrate degradome comparisons identified specific differentially modulated pathways and networks in TAA and AAA. Reverse degradomics elucidated > 300 CMA1 and MMP9 substrate cleavage sites, of which, many, including orthogonally validated biglycan cleavage, occurred in the disease degradomes. ConclusionsUnbiased, proteome-wide forward degradomics of the aortic wall from TAA, AAA and non-diseased tissue generated the first systems biology view of vascular wall breakdown and public resource for the hitherto occult proteolytic landscape, demonstrating widespread extracellular matrix remodeling. The findings provide insights on aortic aneurysm pathways and potential disease biomarkers. Mapping of specific contributions of CMA1 and MMP9 on the aortic forward substrate degradome using reverse degradomics provides a strategy for defining the activities of all proteases involved in aortic disease.

biochemistry↗

bioRxiv2021

Consequences of PDGFRα+ fibroblast reduction in adult murine hearts

Fibroblasts produce the majority of collagen in the heart and are thought to regulate extracellular matrix (ECM) turnover. Although fibrosis accompanies many cardiac pathologies and is generally deleterious, the role of fibroblasts in maintaining the basal ECM network and in fibrosis in vivo is poorly understood. We genetically ablated fibroblasts in mice to evaluate the impact on homeostasis of adult ECM and cardiac function after injury. Fibroblast-ablated mice demonstrated a 60-80% reduction in cardiac fibroblasts, which did not overtly alter fibrillar collagen or the ECM proteome evaluated by quantitative mass spectrometry and N-terminomics. However, the distribution and quantity of collagen VI, a microfibrillar collagen that forms an open network with the basement membrane, was altered. In fibroblast-ablated mice, cardiac function was better preserved following angiotensin II/phenylephrine (AngII/PE)-induced fibrosis and myocardial infarction. Analysis of cardiomyocyte function demonstrated weaker contractions and slowed calcium decline in both uninjured and AngII/PE infused fibroblast-ablated mice. Moreover, fibroblast-ablated hearts had a similar gene expression profile to hearts with physiological hypertrophy after AngII/PE infusion. Our results indicate that the adult mouse heart tolerated a significant degree of fibroblast loss with potential beneficial impacts on cardiac function. Controlled fibroblast reduction may have therapeutic value in heart disease by providing cardioprotective effects.

cell biology↗